Epidemiological studies of patients receiving long-term COX-2 inhibitors indicated a significant decrease in the incidence and the multiplicity of colorectal carcinoma by inhibiting tumor angiogenesis, inducing tumor apoptosis, and preventing hepatic metastasis [32]. The gene discussed is PTGS2; the disease is neoplasm.